Onc.AI to Showcase Breakthrough AI Model and Clinical Trial Data at AACR 2025
Onc.AI, a leader in AI-driven clinical management solutions for oncology, has announced a significant milestone in its collaboration with global biopharma company GSK. The two companies have worked together to evaluate Onc.AI's FDA breakthrough-designated Serial CTRS AI model in GSK’s GARNET Phase I clinical trial. The findings from this study will be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place from April 27, 2025.
Serial CTRS Model in NSCLC Treatment
The study focused on patients with advanced non-small cell lung cancer (NSCLC) who were treated with GSK's anti-PD-1 checkpoint inhibitor, dostarlimab. The research evaluated the performance of the Serial CTRS model, which uses routine CT imaging to predict overall survival (OS) without requiring manual annotations.
The results of the study were presented in a poster session during the Predictive Biomarkers 2 meeting. The findings demonstrated that Serial CTRS significantly outperformed traditional response criteria, such as RECIST 1.1 and tumor volume change assessments, in predicting OS.
Key Findings from the Study
- Improved Prediction of Survival: Serial CTRS was able to more effectively distinguish between patients with intermediate versus high probabilities of 12-month OS, showing a hazard ratio of 2.91, compared to 1.34 for RECIST 1.1 and 1.00 for tumor volume changes.
- Consistent Predictive Performance: Even after adjusting for factors like age, tumor volume, and PD-L1 Tumor Proportion Score (TPS), Serial CTRS remained a significant predictor of OS.
These results reinforce the potential of Serial CTRS as a new standard for automated, AI-driven imaging endpoints that can integrate into clinical workflows, enabling more accurate assessments of treatment response.
The Effect of AI on Clinical Trials for Cancer
Onc.AI CEO Akshay Nanduri welcomed the findings, highlighting the breakthrough's ability to revolutionize clinical oncology. He observed that the collaboration with GSK, along with state-of-the-art deep learning and harmonized imaging data, demonstrates the Serial CTRS model's strength.
George R. Simon, MD, OhioHealth Vice President of Oncology, also emphasized the wider significance of Onc.AI's innovation, proposing that Serial CTRS could transform the clinical development process, from Phase I to Phase III studies.
A Step towards the Future of Oncology
The partnership between Onc.AI and GSK is a major step forward in the application of AI in oncology. Through the use of AI tools such as Serial CTRS in clinical trials, the healthcare sector gets closer to more precise and effective treatment response evaluations. The partnership illustrates how AI technology can redefine the future of cancer treatment.
